# Vedolizumab

## ENTYVIO inj 300mg (infusion)

##### 臨採

| TAH Drug Code      | [IENT](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IENT){:target="_blank"}                                                                                                                                                                                                                                                                                                                                                   |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Crohn disease or ulcerative colitis                                                                                                                                                                                                                                                                                                                                                                                                      |
| Dosing             | IVD, ulcerative colitis, Crohn's disease 300 mg at week 0, 2 and 6, followed by every 8 weeks.                                                                                                                                                                                                                                                                                                                                           |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                            |
| Contraindications  | Hypersensitivity reaction, severe or serious, to vedolizumab or any of its excipients.                                                                                                                                                                                                                                                                                                                                                   |
| Adverse Effects    | Common: Nausea (9%), Arthralgia (12%), Headache (12%), Nasopharyngitis (13%), Upper respiratory infection (7%), Fatigue (6%), Fever (9%) Serious: Aminotransferase abnormal, Increased (Up to 2%), Hepatitis, Serum bilirubin above reference range, Anaphylaxis (0.07%), Hypersensitivity reaction, Progressive multifocal leukoencephalopathy, Tuberculosis, Cancer (0.4%), Infectious disease, Infusion reaction (4%), Sepsis (0.03%) |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                   |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                            |
| More Info          | [UpToDate](https://www.uptodate.com/contents/vedolizumab-drug-information){:target="_blank"}                                                                                                                                                                                                                                                                                                                                             |

## Entyvio inj 108mg/0.68mL 皮下注射

##### 臨採

| TAH Drug Code      | [IENTH](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=IENTH){:target="_blank"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of moderate to severe active ulcerative colitis and moderate to severe active Crohn's disease in adults. In patients who have responded inadequately, lost response, or are intolerant to treatment with tumor necrosis factor (TNF) blockers or immunomodulatory therapy; or in those who have shown inadequate response, intolerance, or demonstrated dependence on corticosteroid therapy.                                                                                                                                                                                                                        |
| Dosing             | After at least 2 intravenous infusions, for maintenance therapy with subQ Entyvio, the recommended dosing regimen is 108 mg SC every 2 weeks. The first subQ dose should replace the next scheduled intravenous dose, followed by subsequent subQ injections every 2 weeks. If subQ Entyvio treatment is interrupted or a dose is missed, instruct patients to administer the next dose as soon as possible, followed by subsequent injections every 2 weeks. In clinical trials, interruptions up to 46 weeks showed no increased adverse events or notable increase in injection site reactions upon reinitiating treatment. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Contraindications  | Known severe or hypersensitive reaction to Entyvio or its excipients, such as difficulty breathing, bronchospasm, urticaria, flushing, rash, and increased heart rate.                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Adverse Effects    | Common: Nausea (9%), Arthralgia (12%), Headache (12%), Nasopharyngitis (13%), Upper respiratory infection (7%), Fatigue (6%), Fever (9%) Serious: Aminotransferase abnormal, Increased (Up to 2%), Hepatitis, Serum bilirubin above reference range, Anaphylaxis (0.07%), Hypersensitivity reaction, Progressive multifocal leukoencephalopathy, Tuberculosis, Cancer (0.4%), Infectious disease, Infusion reaction (4%), Sepsis (0.03%)                                                                                                                                                                                       |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| More Info          | [UpToDate](https://www.uptodate.com/contents/vedolizumab-drug-information){:target="_blank"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

